BRIEF published on 04/22/2025 at 22:05, 7 months 12 days ago Abivax welcomes Dr. Dominik Höchli to its Board of Directors Board Of Directors Abivax Phase 3 Immunology Dominik Höchli
PRESS RELEASE published on 04/22/2025 at 22:05, 7 months 12 days ago Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Abivax announces details of Annual General Meeting on June 6, 2025, in Paris as it progresses towards key 2025 milestones, including Phase 3 ABTECT trials Annual General Meeting Abivax Clinical-stage Biotechnology Phase 3 ABTECT Trials 2025 Milestones
PRESS RELEASE published on 04/22/2025 at 22:00, 7 months 12 days ago Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Abivax appoints Dominik Höchli, MD to Board of Directors, bringing extensive immunology expertise ahead of key Phase 3 data readout in ulcerative colitis in Q3 2025 Board Of Directors Abivax Ulcerative Colitis Dominik Höchli Phase 3 Data Readout
BRIEF published on 04/18/2025 at 18:05, 7 months 16 days ago ABIVAX: Share Capital and Voting Rights as of March 31, 2025 Euronext Paris Share Capital Voting Rights Actions Abivax
BRIEF published on 04/18/2025 at 18:05, 7 months 16 days ago ABIVAX: Details of Share Capital and Voting Rights as of March 31, 2025 Euronext Paris Share Capital Voting Rights Biotechnology Abivax
BRIEF published on 03/27/2025 at 18:05, 8 months 8 days ago ABIVAX: Update of share capital and voting rights Share Capital Voting Rights Biotechnology AMF Abivax
BRIEF published on 03/26/2025 at 22:10, 8 months 9 days ago Abivax publishes its 2024 financial reports Biotechnology AMF Abivax Financial Reports DRY
PRESS RELEASE published on 03/26/2025 at 22:05, 8 months 9 days ago Abivax publishes financial reports with the French and U.S. securities regulatory agencies Abivax publishes financial reports with French and U.S. securities regulatory agencies. The company filed its Universal Registration Document and Annual Report for 2024 Abivax Financial Reports Regulatory Agencies U.S. Securities French
BRIEF published on 03/24/2025 at 08:35, 8 months 12 days ago Abivax Publishes its Financial Results for 2024 Financial Results Biotechnology Research And Development Treasury Clinical Trials
PRESS RELEASE published on 03/24/2025 at 08:30, 8 months 12 days ago Abivax Announces Full Year 2024 Financial Results Abivax announces full year 2024 financial results, cash balance of EUR 144.2M, ABTECT trial progress. CEO optimistic about 2025 milestones and financial outlook Financial Results Cash Position Abivax ABTECT Trial Clinical Progress
Published on 12/05/2025 at 02:35, 9 hours 48 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 11 hours 23 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 13 hours 18 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 13 hours 23 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 12:05, 18 minutes ago Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 23 minutes ago CGTN：Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre
Published on 12/05/2025 at 12:00, 23 minutes ago Iute Group: Successful Issue of Additional EUR 2025/2030 Bonds – Circulating Volume Increased to EUR 160 Million
Published on 12/05/2025 at 11:14, 1 hour 9 minutes ago Halfords Group PLC: Director/PDMR Shareholding
Published on 12/05/2025 at 10:30, 1 hour 53 minutes ago Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 08:45, 3 hours 38 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 18 hours 23 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 18 hours 38 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 18 hours 39 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 5 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
